News
CVM
0.1913
-8.29%
-0.0173
CEL-SCI Announces Study Published In 'Cancer Cell' Confirms Pre-Surgical Tumor Response In Head And Neck Cancer Patients Treated With Its Multikine Improves Overall Survival, Supporting Early Regulatory Approval As A Neoadjuvant Treatment For Locally Advanced Head And Neck Cancer
Benzinga · 19h ago
CEL-SCI says publication supports strategy to seek early approval for multikine
TipRanks · 19h ago
New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI’s Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses
Barchart · 1d ago
Weekly Report: what happened at CVM last week (0331-0404)?
Weekly Report · 1d ago
Weekly Report: what happened at CVM last week (0324-0328)?
Weekly Report · 03/31 11:30
CEL-SCI publishes new data from Multikine study
TipRanks · 03/25 19:48
Weekly Report: what happened at CVM last week (0317-0321)?
Weekly Report · 03/24 11:17
Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket
Benzinga · 03/18 10:04
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 03/17 12:11
Weekly Report: what happened at CVM last week (0310-0314)?
Weekly Report · 03/17 11:28
CEL-SCI Announces That A Third-Party Study Published In Jama Oncology Titled "Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-stratified Chemoradiation Therapy In HPV-Negative Head And Neck Cancer: The DEPEND Phase 2 Non-Randomized Clinical Trial" Provided Data That Support Multikine's Use As A Neoadjuvant Treatment In Patients With Tumors Having Low PD-L1
Benzinga · 03/14 12:32
Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI’s Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression
Barchart · 03/14 07:30
Weekly Report: what happened at CVM last week (0303-0307)?
Weekly Report · 03/10 11:30
Weekly Report: what happened at CVM last week (0224-0228)?
Weekly Report · 03/03 11:29
Weekly Report: what happened at CVM last week (0217-0221)?
Weekly Report · 02/24 11:28
Cel-Sci GAAP EPS of $0.11
Seeking Alpha · 02/18 17:29
CEL-SCI Highlights Multikine's 73% 5-Year Survival Benefit In Low PD-L1 Head And Neck Cancer Patients; New Phase 3 Confirmatory Trial Planned With Ergomed As CRO Partner; Accelerated Approval Possible In 2026 Based On Tumor Response Data
Benzinga · 02/18 13:42
*CEL-SCI: FDA Concurred With Co's Plan to Use of PD-L1 as Biomarker to Patients for Phase 3 Confirmatory Trial >CVM
Dow Jones · 02/18 13:38
*CEL-SCI 1Q Loss/Shr 11c >CVM
Dow Jones · 02/18 13:34
Press Release: CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks
Dow Jones · 02/18 13:30
More
Webull provides a variety of real-time CVM stock news. You can receive the latest news about CEL-SCI Corp through multiple platforms. This information may help you make smarter investment decisions.
About CVM
More
CEL-SCI Corporation is a late clinical-stage biotechnology company. It is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. It is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).